Abstract. Software is becoming increasingly important and pervasive in healthcare. Deads and injuries, recalls related to the medical software, defective medical device statistics justify the practical dimension of the issue and needs to search ways seeking reduce possibility to arise injuries and deaths. Decision to release medical software to the market is very important not only to the manufacturer (design and development organization), but also for direct and indirect users (doctors and patients) and for all society, which is using national medical system with integrity information technologies possibilities. Manufacturers of medical devices assume responsibility for the correct functioning of medical devices and medical software manufacturer should assume responsibility for medical decisions making and medical decision influence on patient. This responsibility is related not only to the legal and financial risk, but also to the socially responsible business commitments. Software developing companies does not have knowledges about the conditions, which can assure medical software confidence before the release to the market. Such situations stops entrepreneur involvement in the medical software creating area.
Introduction
One of the areas of significant growth in medical devices has been the role of software -as an integral component of a medical device, as a standalone device and more recently as applications on mobile devices. Software is becoming increasingly important and pervasive in healthcare. Given the availability of a multitude of technology platforms (e.g., personal computers, smart phones, network servers, etc.), as well as increasing ease of access and 1 
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The International Journal ENTREPRENEURSHIP AND SUSTAINABILITY ISSUES ISSN 2345-0282 (online) http://jssidoi.org/jesi/ 2016 Volume 4 Number 2 (December) distribution (e.g., internet, cloud), software created for medical purposes (software used to make clinical decisions) and non-medical purpose (e.g., administrative, financial) are being used in healthcare. Manufacturers of medical devices assume responsibility for the correct functioning of medical devices and medical software manufacturer should assume responsibility for medical decisions making and medical decision influence on patient. This responsibility is related not only to the legal and financial risk, but also to the socially responsible business commitments. Decision to release medical software to the market is very important not only to the manufacturer (design and development organization), but also for direct and indirect users (doctors and patients) and for all society, which is using national medical system with integrity information technologies possibilities.
The problem, analyzed in this article, can be formulate as a question "How to manage the risk of business development of medical software creation for IT sector organizations?" Identified problem leads to the goal -to find algorithm, which comply with the legal requirements and would be useful and helpful to the medical software manufacturers.
The main tasks and research results would be following:
-Describe advanced research scope. This task creates possibility to identify limitations related to the medical software and created management decisions algorithm for sustainable development. -Describe legal environment in different countries. This task helps to evaluate focus of legal requirements to the medical devices in different countries. -Formulate of socially responsible solution assumption. This task helps to evaluate, how can be measured benefit of algorithm. -Describe the adviced algorithm. This task helps to set sequencion and interaction of proposed actions, internal and external risk identification sources, which influence management decision. -Describe how the algorithm was adopted for the "Softneta" medical device case. This task result must show algorithm adaptation results in user/ patient safety and medical software reliability aspects. -Describe benefit of biomedical trials. This task results must show justification, why biomedical trials stage is necessary and useful. -Research object. "Softneta" is medical software creating organization. This implies the need to comply with the Lithuanian legal requirements for the medical devices. Case study is applied to the stand-alone medical device: software MedDream WEB DICOM Viewer. Indications for Use: MedDream WEB DICOM Viewer is as software medical imaging system used to receive DICOM images, scheduling information and textual reports, organize and store them in an internal format, and to make that information available across a network via web and customizes user interfaces. Software is intended for use as a diagnostic, review and analysis tool by trained professionals such as radiologists, physicians, clinicians. Contraindications: The MedDream is not intended for the acquisition of mammographic image data and is meant to be used by qualified medical personnel only who are qualified to create and diagnose medical image data.
According to the intended use of the device, MedDream is a stand-alone software that is specifically intended to be used for diagnostic purposes by viewing, archiving and transmitting of medical images. As it is not only suited for archiving or storage of data, it falls within the definition of an active medical device for diagnosis. MEDDEV 2.1/6 Annex 1 c1.4) links to the Manual on Borderline and Classification in the Community Regulatory Framework for Medical Devices, as it addresses the issue of PACS software systems. MedDream has no postprocessing functions, as well as no control of image acquisition. Also it doesn't drive any other medical device, nor influence the use of a medical image source device, so implementing rule 2.3 "Software, which drives a device or influences the use of a device, falls automatically in the same class." is not applicable and standalone software could be classified in its own right. MedDream allow direct diagnosis from image, also can apply multi- To ensure safety creation and maintenance medical software, which belongs to the Class IIa medical devices, should be implemented EU requirements for medical software. Medical software distribution in USA conditions requires FDA (Food and Drug Administration) approval/ clearancy, therefore FDA requirements for medical devices also should be implemented and maintained.
Softneta" present their social responsibility by creating rationale management decisions algorithm for sustainable development. This algorithm, created according to the medical devices related legal requirements, standards and good design and development practices, gives answer to the question "when the medical software ensures enough reliability and can be released to the market?" and eliminate restrictions, therefore can be used by other medical software creating organizations.
Methods applied: literature review was used for the article problem justification. Identified problem relevance was approved and legal environment analysis was made by analyzing primary and secondary data sources. Legal requirement analysis results were presented by using benchmarking. "Softneta" case study results were analyzed by using statistical analysis. Conclusion were formulated by using induction and deduction principles.
Literature review. In the US alone, iatrogenic or medical errors are responsible for 100.000 deaths and injuries every year (Kohn, Corrigan, Donaldson, 2000) . Dr. Martin Makary claims that medical errors are now the third leading cause of death in the US (Makary M., 2016). The total cost of all medicinal errors in the US has accumulated to approximately 50 billion $ (Bond, Dewar, Finlay, Nugent, Moore, Guldenring, 2014) . European data, mostly from European Union Member States, consistently show that medical errors and health-care related adverse events occur in 8% to 12% of hospitalizations. For example, the United Kingdom Department of Health, in its 2000 report An organisation with a memory, estimated about 850 000 adverse events a year (10% of hospital admissions). Spain (in its 2005 national study of adverse events) and France and Denmark have published incidence studies with similar results. Infections associated with health care affect an estimated 1 in 20 hospital patients on average every year (estimated at 4.1 million patients) with the four most common types being: urinary tract infections (27%), lower respiratory tract infections (24%), surgical site infections (17%) and bloodstream infections (10.5%). Multiresistant Staphylococcus aureus (MRSA) is isolated in about 5% of all infections associated with health care. The United Kingdom National Audit Office estimates the cost of such infections at £1 billion per year. While 23% of European Union citizens claim to have been directly affected by medical error, 18% claim to have experienced a serious medical error in a hospital and 11% to have been prescribed wrong medication. Evidence on medical errors shows that 50% to 70.2% of such harm can be prevented through comprehensive systematic approaches to patient safety. This statistics, given from World Health Organization regional office for Europe, show that strategies to reduce the rate of adverse events in the European Union alone would lead to the prevention of more than 750 000 harm-inflicting medical errors per year, leading in turn to over 3.2 million fewer days of hospitalization, 260 000 fewer incidents of permanent disability, and 95 000 fewer deaths per year. Above mentioned information creates conditions to think about error prevention. P. Croskerry, D. Sinclair (2001) says that the "science of error prevention" has been deemed a new, yet important topic in medicine. One of the most important causes of medical error can be called as wrong uses of medical devices and/or disfunction of medical devices. It is very important to reduce possible medical devices disfunctions which can lead to patient injury or death. Responsible behavior requires medical software quality and reliability assurance from the developing organizations and helps to ensure social responsibility in hospital governance, which is mentioned as a "new paradigm of hospital governance" (Brandao, Rego, Duarte, Nunes, 2013) .
Importance of this new parading shows a lot of articles, written by Keyvanara, Sajadi (2015) , Liu, Shi, Pong, Chen (2016) , Hsieh, Chiu, Hsieh, Ho, Chen, Chang (2016) , Iyngkaran, Beneby (2015) . Social entrepreneurship, analyzed by Roper, Cheney (2001) , Hoogendoorn, Pennings, Thurik (2010) 2008-2011, 45% of the devices recalled were pulled from the market due to a manufactural defect. -29% of the recalled devices malfunctioned during use or failed to provide intended results.
-11% of the medical devices recalled during this period were found to be contaminated in some way.
-The 510(k) program is an approval system that allows the manufacturers of medical devices to bring products to market without first performing clinical trials to ensure product safety and reliability. Manufacturers must only proof that the device is similar to existing devices on the market in order to gain approval through this system. -71% of high risk devices that have gained approval through the 510(k) program were later recalled.
-Revisions have been made to this approval process in 2013 in hopes that stricter standards will reduce the number of harmful products allowed to make it to market. Software developing companies does not have knowledges about the conditions, which can assure medical software confidence before the release to the market. Even more, no one insurance company in Lithuania does not offer insurance for patient injury cases. Such situations stops entrepreneur involvement in the medical software creating area.
"Softneta" case study analysis scheme for searching rationale management decisions for sustainable development is presented below (Fig.1 
Advanced research scope
Advanced research scope gives more detailed information about the medical software: -Definition and description of device or product, and intended use. MedDream WEB DICOM Viewer is a Flash/HTML based package for PACS server which is designed to aid professionals in everyday's decision making process, connecting all the medical data into a unified and fast performing network. MedDream ensures a fast and reliable way to search, present and analyze the medical data (images and video files) on various devices: computers, smart phones, tablets (near future) and so forth. The system consists of hardware (eg., a network switch, controller) and server / client software (eg., as the final decision) for the transfer of image data from a variety of video / audio and video devices (eg. endoscopic camera, an ultrasound imaging system, radiography digital video system) to standard devices (eg., monitor, personal computer [PC] ). Standalone software is considered to be an active medical device, therefore MedDream WEB DICOM Viewer is considered to be an active medical device. MedDream WEB DICOM Viewer was created to use it for medical devices images management. Indications for Use: MedDream is as software medical imaging system used to receive DICOM images, scheduling information and textual reports, organize and store them in an internal format, and to make that information available across a network via web and customizes user interfaces. Software is intended for use as a diagnostic, review and analysis tool by trained professionals such as radiologists, physicians, clinicians. Contraindications: The MedDream is not intended for the acquisition of mammographic image data and is meant to be used by qualified medical personnel only who are qualified to create and diagnose medical image data -GMDN Code: Medical image management system: A computerized system designed to electronically receive, collect, store, and display a broad range of medical imaging/video data, including patient Limitations related to the medical software and created management decisions algorithm for sustainable development are mentioned below. Algorythm is applicable only for medical software, which is/has: -classified not risky as IIa class.
-recognized as"moderate" managing level.
-no tangible product of expression; -not required of any material; -an exception on requirements for sterile medical devices/ this requirement is not applicable. so there is no risk to mix sterile and non-sterile products. -integrated into the devices, which are not intended to give medication to the patients.
-no components and devices to which software is integrated, can't be treated as pharmaceuticals (also are not intended to give medication to the patients).
Legal environment: requirement in Lithuania, EU and USA
In general, existing regulations address public health risks of medical software. However, the current application of regulations and controls may not always translate or address the unique public health risks posed by Software as a Medical Device nor assure an appropriate balance between patient/consumer protection and promotion of public health by facilitating innovation (White Paper "Software Development for Medical Devices"). Some regulators have taken individual approaches to assure safety, effectiveness, and performance of Software as a Medical Device. Such approaches have common public health goals. Lithuanian legal requirements highlights reliability based on biomedical researches, EU legal requirements highlights reliability based on risk management and clinical evaluation and USA legal requirements highlights reliability based on internal verification and validation, risk management. White Paper "Software Development for Medical Devices" reviews some of the key challenges facing the medical device industry. One of the mentioned challenges is "managing risk and reducing recalls". Global software development solutions (simplified electronic tracking of requirements, risks and mitigations with relationships and dependencies; automatically compute Risk Priority Number (RPN); automated support for V-Model with named relationships between requirements, design, and software assets and their associated verification and validation assets) creates benefits: reduced risk, improving productivity while maintaining compliance and managing risk (White Paper "Software Problem description: In very rare cases, some of the data stored in the CONTOUR CLOUD could be incomplete (Urgent fiels safety notice "Conour TM Diabetes APP and Contour Cloud Synchronization Customer Email").
Assumption for socially responsible solution and algorithm for management decision to release medical software ensuring reliability
Decision to release medical software should be made when manufacturer can assure reliability. Reliability can be translated in to the measuring units and could have mathematical expression, further mentioned as risk/benefit calculation, as shown below:
, where uc -user count (further medical software version user count or planned medical software user count) clc -count of code lines (programinės įrangos eilučių skaičius) rc -count of risks (total count of residual risks) cos -coeficien), which is classified according to the overall residual risk estimate.
If the risk/benefit value (in percent) is less than 1 (one), considered that the software benefits outweigh the risks that may be encountered while using the software. If the software utility is equal to the risk (the risk-benefit ratio as a percentage value is equal to 1 (one) or less than the potential risks (that is greater than 1), then the version of the software can't be released to the market.
Clinical evaluation (as presented it the Figure 2) , lasting during the whole design and development process, helps to identify critical issues for potential risk. Abowe (in Figure 3) it is presented algorithm used by "Softneta" aiming to ensure the possible lowest residual risk results.
Algorithm adaptation for "Softneta" medical software "MedDream WEB DICOM Viewer" case
Risk assessment results, based on real "Softneta" medical software data, presented in the table below ( Table 2 ).
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As shown in the table 2, decision to release medical software to the market should be made before post market follow-up. It means, that possible risks may arise after the release. Implemented actions before the decision to release medical software to the market ensure low possibility to identify many risks during the post market follow-up period. Previous "Softneta" case studies shows, that new arised risk is not exceed 7 percent. In this case study foreseen 3 percent inaccuracy leads to the 10 percent possible risk, identified during the post market follow-up period. Case study results shows, that decision to release medical software to the market were made when 76,5 percent risk (from the 90 percent identified risk) (or 85 percent from 100 percent identified risk (if all risk, identified during the actions before decision making, equals 100 percent)) cases were solved. Not eliminated risk is treated as known bugs and would be given to the users as a part of IFU (Instructions for users).
Calculated risk/benefit results by release the medical software were 0,00002. It means, that the software benefits outweigh the risks that may be encountered while using the software. This result shows probability to arise 141 problem/complain in 2 of 100 000 cases (or 1 of 50 000 cases). Risk, related to software functions, which can lead to injury, were eliminated. According to the algorithm, the new risk (10 percent) can arise during the post market follow-up period. If the new risk would be identified, the worst risk/benefit result can reduce risk/benefit results 10 percent. In such case risk/benefit results would be 0,000022 (probability to arise problem/complain in 22 of 1 000 000 cases (1 of 45 455 cases). In "Softneta" case this result assure reliability of the medical software (number of users does not exceed 100 000). Other organizations, working according to the presented algorithm, should interpret results in their context and have justification for the made decision to release medical software to the market. One inexperienced injury can be evaluated using the data from insurance policy: 1 000 000 EUR for each and every claim, including cost and expenses. The Table 3 , presented below, shows the benefits of applying the algorithm. Risk/benefit score can be calculated having primary information not only about risk, but also about the count of code lines. This data can be firstly used in stage of design and development. Each algorithm action helps to reduce probability to arise problems/injury and shows possible result if any actions could be not implemented.
Benefit of biomedical trials -a separate stage for external evaluation
In order to know biomedical trials impact to the management decision to release medical software to the market, the biomedical trials were implemented. Data, presented in This biomedical evaluation were implemented for Medical Software product Meddream Web DICOM Viewer for the purpose to ensure maximum patient safety using this software. The main tasks of biomedical evaluation:
-To verify that the fully integrated and final system to be delivered meets the specification and its purpose; -To get a confirmation from the user that system is accepted and solves those business problems for whitch it was designed to automate; -Performance: if Meddream Viewer achieves the performances intended by Softneta UAB; -Safety: if undesirable side-effects, under normal conditions of use, are acceptable when weighed against the benefits to the patient. -To determine any undesirable side effects and to make sure that the side effects by normal usage environment are acceptable risks (weighed against the intended operation of the medical device). Data, presented in table 4, leads to thinking, that biomedical trials is very important actions, which can essure better reliability of medical software.
Conclusions
Manufacturers of medical devices assume responsibility for the correct functioning of medical devices and medical software manufacturer should assume responsibility for medical decisions making and medical decision influence on patient. This responsibility is related not only to the legal and financial risk, but also to the socially responsible business commitments.
Software developing companies does not have knowledges about the conditions, which can assure medical software confidence before the release to the market. Even more, no one insurance company in Lithuania does not offer insurance for patient injury cases. Such situations stops entrepreneur involvement in the medical software creating area.
"Softneta" present their social responsibility by creating rationale management decisions algorithm for sustainable development. This algorithm, created according to the medical devices related legal requirements, standards and good design and development practices, gives answer to the question "when the medical software ensures enough reliability and can be released to the market?" and eliminate restrictions, therefore can be used by other medical software creating organizations.
The current application of regulations and controls may not always translate or address the unique public health risks posed by Software as a Medical Device nor assure an appropriate balance between patient/consumer protection and promotion of public health by facilitating innovation.
Case study is applied to the stand-alone medical device: software MedDream WEB DICOM Viewer, which is classified as a Class IIa active medical device and for the safety creation and maintenance conditions, also for the selling conditions should comply Lithuanian, EU and USA (FDA) legal requirements. 
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Lithuanian legal requirements highlights reliability based on biomedical researches, EU legal requirements highlights reliability based on risk management and clinical evaluation and USA legal requirements highlights reliability based on internal verification and validation, risk management. All this approach are integrated by creating algorithm for management decisions for sustainable development (for the decision to release medical software to the market).
Algorythm is applicable only for medical software, which is/has classified not risky as IIa class; recognized as"moderate" managing level; no tangible product of expression; not required of any material; an exception on requirements for sterile medical devices/ this requirement is not applicable. so there is no risk to mix sterile and non-sterile products; integrated into the devices, which are not intended to give medication to the patients; no components and devices to which software is integrated, can't be treated as pharmaceuticals (also are not intended to give medication to the patients).
Decision to release medical software should be made when manufacturer can assure reliability. Reliability can be translated in to the measuring units and could have mathematical expression, which advices authors.
Medical software reliability depends on risk management results, using clinical evaluation data during the whole design and development process.
Algorithm for management decision to release medical software ensuring reliability were used by "Softneta" in order to ensure the possible lowest residual risk results.
Case study results shows, that decision to release medical software to the market were made when 76,5 percent risk (from the 90 percent identified risk) (or 85 percent from 100 percent identified risk (if all risk, identified during the actions before decision making, equals 100 percent)) cases were solved. Not eliminated risk is treated as known bugs and would be given to the users as a part of IFU (Instructions for users).
Calculated risk/benefit results by release the medical software were 0,00002. It means, that the software benefits outweigh the risks that may be encountered while using the software. This result shows probability to arise problem/complain in 2 of 100 000 cases (or 1 of 50 000 cases). Risk, related to software functions, which can lead to injury, were eliminated.
According to the algorithm, the new risk (10 percent) can arise during the post market follow-up period. If the new risk would be identified, the worst risk/benefit result can reduce risk/benefit results 10 percent. In such case risk/benefit results would be 0,000022 (probability to arise problem/complain in 22 of 1 000 000 cases (1 of 45 455 cases).
By the calculating probability to arise problems/injury before and afer the implemented actions algorithm action helps to reduce probability to arise problems/injury and shows possible result if any actions could be not implemented.
Biomedical trials -a separate stage for external evaluation shows that biomedical trials were very important seeking to essure better reliability of medical software (reduced probability to arise problems/injury from 1 of 45 455 cases till 1 of 50 000 cases.
Financial benefit of biomedical trials can be calculated using data from insurance policy: 1 000 000 EUR for each and every claim, including cost and expenses.
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To ensure case studies results extension for the summarized calculation about each algorithm implementation stage, the case study schould be replicated to the other medical software creating organizations.
